Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.55 |
| ▸ | MMP3 | P08254 | 16/20 | 0.41 |
| ▸ | MMP2 | P08253 | 15/20 | 0.41 |
| ▸ | MMP7 | P09237 | 13/20 | 0.41 |
| ▸ | MMP1 | P03956 | 14/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | FCER2 | P06734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7955135 | 1.00 | ADAM17 (0.55) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL1844380 | 1.00 | ADAM17 (0.55) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL7955133 | 1.00 | ADAM17 (0.55) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL13274078 | 1.00 | ADAM17 (0.55) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL7836742 | 0.94 | ADAM17 (0.48) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL7835742 | 0.94 | ADAM17 (0.48) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL7836616 | 0.90 | ADAM17 (0.53) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL7960536 | 0.88 | ADAM17 (0.43) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL7837198 | 0.88 | ADAM17 (0.43) | ADAM17MMP3MMP2MMP7MMP1 | |
| SCHEMBL7837197 | 0.88 | ADAM17 (0.43) | ADAM17MMP3MMP2MMP7MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226922-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2010-09-09 | — | — | US | claimed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | claimed |
| EP-2041181-B1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100226922-A1 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1865001-A1 | Specific protease inhibitors and their use in cancer therapy | GSF-FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT, GMBH (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-6281363-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; AUTOIMMUNE DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | ADAM17 22/4885MMP3 39/4885MMP2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.